TAOX

TAO Synergies Inc. (TAOX) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. TAO Synergies Inc. (formerly Synaptogenix, Inc.) has pivoted from a biopharmaceutical developer to a company employing a cryptocurrency treasury strategy focused on TAO, the native token of the Bittensor decentralized AI network. While the company retains its biopharmaceutical assets (Bryostatin-1), its primary operational focus and revenue generation now stem from staking TAO tokens and holding digital assets.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Generation: The company recorded $388,774 in revenue from TAO staking, compared to zero in the prior year. This marks the first quarter of operational revenue under the new strategy.
• Profitability Surge: Net income increased by over 1,000% to $4.25 million. This is primarily driven by a $6.84 million unrealized gain on digital assets and a $350,740 gain on Yuma partnership investments, rather than core operating profitability.
• Expense Increases: General and Administrative (G&A) expenses rose 66.4% to $1.68 million, driven by higher legal fees, consulting services (including non-cash warrant issuances to crypto experts), and increased insurance premiums for the crypto strategy. R&D expenses decreased 53% to $28,600 as clinical trials were paused or concluded.
• Balance Sheet Shift: Cash reserves decreased by approximately $1.85 million, while digital asset holdings increased by over $7.2 million (from $17.9M to $25.2M), reflecting the deployment of cash into the TAO treasury strategy.
• Derivative Liabilities: The derivative liability associated with Series E Convertible Preferred Stock increased by $1.65 million to $3.76 million, negatively impacting other income.

Guidance, Outlook, and Risks

• Treasury Strategy: Management intends to allocate 75% to 100% of "excess cash" (cash beyond 1.5–2.0 years of operating needs) to purchasing TAO. The company holds approximately 82,210 TAO tokens, with the majority staked via BitGo and Yuma validators.
• Liquidity: Management believes current cash and digital asset values (~$28 million) are sufficient to fund operations for at least the next 12 months. However, additional capital may be required to pursue the TAO strategy further or advance biopharmaceutical programs.
• Biopharmaceutical Status: The company is evaluating plans for its Bryostatin-1 program. The FDA has placed the IND for a Fragile X trial on clinical hold pending further analytics. The Mount Sinai license agreement was terminated in February 2026.
• Internal Controls: The company disclosed that its disclosure controls and procedures are not effective due to material weaknesses, including inadequate segregation of duties, ineffective financial reporting processes, and weak IT general controls.
• Risks: Significant risks include volatility in TAO prices, reliance on third-party custodians (BitGo), potential inability to raise capital on favorable terms, and the dilutive impact of preferred stock conversions and warrant exercises.

Investor Verification Checklist

• Digital Asset Valuation: Verify the fair value of TAO holdings ($25.2M) against current market prices, noting the significant unrealized gain driving net income.
• Cash Burn Rate: Review the $1.68 million net cash used in operating activities to assess runway given the reduction in cash reserves.
• Preferred Stock Obligations: Examine the terms of Series D and Series E Convertible Preferred Stock, specifically the $11 million liquidation preference of Series E and the accretion/dividend impacts on common equity.
• Internal Control Remediation: Assess management's plan to address the material weaknesses in internal controls over financial reporting.
• Biopharma Pipeline: Confirm the status of the FDA clinical hold on the Fragile X trial and the strategic decision-making regarding the termination of the Mount Sinai license.